SCHEMBL9326003

SCHEMBL9326003

ON=CCC1CCCCC1

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADH1B P00325 1/20 0.34
ADH1C P00326 1/20 0.34
ADH1A P07327 1/20 0.34
ADH4 P08319 1/20 0.34
ADH7 P40394 1/20 0.34
CHRM5 P08912 2/20 0.32
CYP1A2 P05177 1/20 0.32
ADRA2C P18825 1/20 0.32
CHRM2 P08172 1/20 0.32
CHRM4 P08173 1/20 0.32
CHRM1 P11229 1/20 0.32
EPHX1 P07099 2/20 0.31
HPGD P15428 1/20 0.31
KMT2A Q03164 1/20 0.31
ALOX5 P09917 1/20 0.31
SIGMAR1 Q99720 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30081303 1.00 ADH1B (0.34) ADH1BADH1CADH1AADH4ADH7
SCHEMBL5584080 0.86
SCHEMBL5584079 0.86
SCHEMBL20640999 0.86
SCHEMBL1587405 0.75 CYP1A2 (0.39) ADH1BADH1CADH1AADH4ADH7
SCHEMBL6535865 0.75 TSHR (0.47) EPHX1
SCHEMBL548442 0.72
SCHEMBL3848698 0.71 ADH1B (0.40) ADH1BADH1CADH1AADH4ADH7
SCHEMBL2021416 0.71 ADH1B (0.40) ADH1BADH1CADH1AADH4ADH7
SCHEMBL6873949 0.71 ADH1B (0.40) ADH1BADH1CADH1AADH4ADH7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827638-B2 Imidazopyrrolopyridine as inhibitors of the JAK family of kinases JANSSEN PHARMACEUTICA NV (BE) 2023-11-28 US disclosed
EP-3555096-B1 IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES JANSSEN PHARMACEUTICA NV (BE) 2022-11-23 EP disclosed
US-20210206768-A1 IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES JANSSEN PHARMACEUTICA NV (BE) 2021-07-08 US disclosed
US-10981911-B2 Imidazopyrrolopyridine as inhibitors of the JAK family of kinases JANSSEN PHARMACEUTICA NV (BE) 2021-04-20 US disclosed
US-20190322665-A1 IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES JANSSEN PHARMACEUTICA NV (BE) 2019-10-24 US disclosed
EP-0334125-B1 Low density silicone foam GEN ELECTRIC (US) 1994-06-08 EP disclosed
EP-0280499-B1 Novel aminohydrocarbyl-substituted ketoximosilanes DOW CORNING (US) 1994-04-13 EP disclosed
EP-0281305-B1 Method for preparing aminohydrocarbyl-substituted ketoximosilanes DOW CORNING (US) 1994-03-09 EP disclosed
EP-0417167-A1 PROCESS FOR THE SYNTHESIS OF O-SUBSTITUTED OXIME COMPOUNDS AlliedSignal Inc. (US) 1991-03-20 EP disclosed
WO-1989011473-A1 PROCESS FOR THE SYNTHESIS OF O-SUBSTITUTED OXIME COMPOUNDS ALLIED-SIGNAL INC. (US) 1989-11-30 WO disclosed
EP-0334125-A2 Low density silicone foam GENERAL ELECTRIC COMPANY (US) 1989-09-27 EP disclosed
US-4808634-A KETOXIME ADDITIVE TO REDUCE FOAM DENSITY GENERAL ELECTRIC COMPANY (US) 1989-02-28 US disclosed
EP-0158159-B1 PROCESS FOR THE SYNTHESIS OF O-SUBSTITUTED OXIME COMPOUNDS AND THE CONVERSION THEREOF INTO THE CORRESPONDING HYDROXYLAMINE O-SUBSTITUTED AlliedSignal Inc. (US) 1988-10-05 EP disclosed
EP-0281305-A2 Method for preparing aminohydrocarbyl-substituted ketoximosilanes DOW CORNING CORPORATION (US) 1988-09-07 EP disclosed
EP-0280499-A2 Novel aminohydrocarbyl-substituted ketoximosilanes DOW CORNING CORPORATION (US) 1988-08-31 EP disclosed
US-4705878-A Method for preparing aminohydrocarbyl-substituted ketoximosilanes DOW CORNING CORPORATION (US) 1987-11-10 US disclosed
US-4705877-A Novel aminohydrocarbyl-substituted ketoximosilanes DOW CORNING CORPORATION (US) 1987-11-10 US disclosed
EP-0158159-A1 Process for the synthesis of o-substituted oxime compounds and the conversion thereof into the corresponding hydroxylamine o-substituted AlliedSignal Inc. (US) 1985-10-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827638-B2 Imidazopyrrolopyridine as inhibitors of the JAK family of kinases JAK1, JAK2, JAK3 ADH1B 4535/4885ADH1C 2290/4885ADH1A 2918/4885
US-20210206768-A1 IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES JAK1, JAK2, JAK3 ADH1B 4535/4885ADH1C 2290/4885ADH1A 2918/4885
US-10981911-B2 Imidazopyrrolopyridine as inhibitors of the JAK family of kinases JAK1, JAK2, JAK3 ADH1B 4535/4885ADH1C 2290/4885ADH1A 2918/4885
US-20190322665-A1 IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES JAK1, JAK2, JAK3 ADH1B 4535/4885ADH1C 2290/4885ADH1A 2918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.